Pharmaceuticals Japan

Japan Amyloidosis Treatment Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Japan Amyloidosis Treatment Market Industry Trends and Forecast to 2034: Segmented by (Type, Drug Class, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Japan · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $554.8 Mn Placeholder estimate
Estimate 2025 $633.6 Mn 7% of the global market
Projected 2034 $2.09 Bn 230.4% Adds $1.46 Bn over 9 forecast years
CAGR 2025–2034 14.2% Faster than 73% of 180 Pharmaceuticals markets here
Key players 5
  • Japan is 6.96% of the global market.
  • In APAC, the largest is China at $787.3 Mn.
  • Fastest growing: India at 17% a year.
  • Japan ranks 2nd of 10 by size in APAC.

Market size projection

Japan

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.46 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Amyloidosis Treatment Market market size by year, Japan
YearMarket sizeChange that yearSince 2025
2024 (estimate) $554.8 Mn — —
2025 (base) $633.6 Mn +$78.8 Mn —
2026 (forecast) $723.5 Mn +$90.0 Mn +14.2%
2027 (forecast) $826.3 Mn +$102.7 Mn +30.4%
2028 (forecast) $943.6 Mn +$117.3 Mn +48.9%
2029 (forecast) $1.08 Bn +$134.0 Mn +70.1%
2030 (forecast) $1.23 Bn +$153.0 Mn +94.2%
2031 (forecast) $1.41 Bn +$174.7 Mn +121.8%
2032 (forecast) $1.60 Bn +$199.6 Mn +153.3%
2033 (forecast) $1.83 Bn +$227.9 Mn +189.3%
2034 (forecast) $2.09 Bn +$260.3 Mn +230.4%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Japan Amyloidosis Treatment Market Analysis at a glance
Market size, 2025$633.6 Mn placeholder estimate
Forecast, 2034$2.09 Bn placeholder estimate
Growth (CAGR), 2025–203414.2% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsType, drug class and end user (see all)
Key playersPfizer Inc., Alnylam Pharmaceuticals, Ionis Pharmaceuticals, BridgeBio Pharma, AstraZeneca (see all)
Regulator in JapanPMDASource: Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
Active clinical trials27 in JapanSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Japan. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Japan Amyloidosis Treatment Market Analysis Executive Summary

Amyloidosis treatments stop or slow the build-up of abnormal proteins that damage the heart and nerves.

Key segments of the amyloidosis Treatment market include type (ATTR Amyloidosis and AL Amyloidosis) and drug class (TTR Stabilizers, TTR Silencers and Chemotherapy and Antibodies).

Bar chart: Japan Amyloidosis Treatment market size, 2024–2034, placeholder estimates. $554.8 Mn in 2024, $633.6 Mn in 2025 and $2.09 Bn in 2034, 14.2% CAGR.
Japan Amyloidosis Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Japan Amyloidosis Treatment Market Dynamics

Market Growth Drivers

Better genetic diagnosis, orphan drug incentives, patient advocacy and new gene and enzyme therapies are driving the amyloidosis Treatment market. More countries now have national rare disease plans.

Opportunity

Newborn genome screening, gene therapies and access programmes in emerging markets give the amyloidosis Treatment market strong growth.

Market Restraints

Very small patient numbers, long diagnosis delays, high treatment prices and limited specialist centres hold back the amyloidosis Treatment market.

Competitive Landscape for Amyloidosis Treatment Market in Japan

The amyloidosis Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Amyloidosis Treatment Market in Japan

Amyloidosis Treatment in Japan: rules, payment and research

Drugs are reviewed by the Pharmaceuticals and Medical Devices Agency (PMDA) and approved by the Ministry of Health, Labour and Welfare (MHLW).⁠[1] Everyone is covered by public health insurance, and the Ministry of Health, Labour and Welfare sets the official price list for covered medicines (NHI prices).⁠[2] ClinicalTrials.gov lists 27 studies on Amyloidosis Treatment that are recruiting, active or about to start in Japan.⁠[3]

[1] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[2] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Japan. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for amyloidosis Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Japan.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Amyloidosis Treatment right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Amyloidosis Treatment in context

Japan compared

  • Health spending per person: 3,638 US$ per person (2023). World: 1,317 US$ per person (2023). 4th highest of the 15 countries we cover in APAC.[1]
  • Doctors: 2.65 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 5th highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 30.0% of people (2025). World: 10.4% of people (2025). Highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 17 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 18 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 18 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Amyloidosis Treatment market in Japan?
Placeholder estimate: about $633.6 Mn in 2025, rising to about $2.09 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Amyloidosis Treatment market in Japan growing?
Placeholder estimate: about 14.2% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Amyloidosis Treatment market report cover?
The report splits the market by type (ATTR Amyloidosis, AL Amyloidosis), drug class (TTR Stabilizers, TTR Silencers, Chemotherapy and Antibodies) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Amyloidosis Treatment market?
Key players include Pfizer Inc., Alnylam Pharmaceuticals, Ionis Pharmaceuticals, BridgeBio Pharma and AstraZeneca.
What is driving the Amyloidosis Treatment market?
Better genetic diagnosis, orphan drug incentives, patient advocacy and new gene and enzyme therapies are driving the amyloidosis Treatment market. More countries now have national rare disease plans.
Who regulates Amyloidosis Treatment in Japan?
Drugs are reviewed by the Pharmaceuticals and Medical Devices Agency (PMDA) and approved by the Ministry of Health, Labour and Welfare (MHLW). Source: Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
How is healthcare paid for in Japan?
Everyone is covered by public health insurance, and the Ministry of Health, Labour and Welfare sets the official price list for covered medicines (NHI prices). Source: Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.
How many clinical trials on Amyloidosis Treatment are running in Japan?
27 studies are recruiting, active or about to start in Japan, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Japan. Retrieved 12 Nov 2026.
How much research is published on Amyloidosis Treatment?
PubMed lists 33 papers on Amyloidosis Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Japan

See all

Related on rare diseases and cardiovascular

See the topic